Lymphoproliferative disorder in a posttransplant setting has emerged as a difficult problem in kidney transplantation (KT).
INTRODUCTION
Kidney transplantation (KT) is an emerging option for renal replacement therapy that improves the quality of life, as compared to dialysis. However, immunosuppressive therapy for the prevention of rejection can lead to lymphoproliferative disease after KT up to 1% to 20% (1) . The extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type that belonged to the indolent B-cell lymphomas which is mainly an observed gastric mucosa and it is associated with the Helicobacter pylori infection (2) (3) (4) (5) , has been rarely reported as originating from other sites. We herein report a case of a KT recipient who is diagnosed with extranodal marginal zone lymphoma involving both conjunctivae.
CASE REPORT
A 37-year-old woman with end-stage renal disease due to lupus nephritis received a living-donor KT after 5 years of peritoneal dialysis. The donor was her mother, and the human leukocyte antigen mismatch number was 2. She underwent induction therapy by using basiliximab, and thereafter maintained immunosuppression with tacrolimus, mycophenolic acid, and deflazacort. The trough level of tacrolimus has been maintained between 4∼5 ng/mL. The allog- It is generally known that MALT lymphoma most frequently develops in the stomach due to the H. pylori in-fection (12) . Only rare nongastric MALT lymphomas with lung, salivary gland, small bowel, colon, or cutaneous involvement have been described in the post-transplant setting (13, 14) . Reports of post-transplant orbital and ocular lymphomas were rarely reported probably due to the scarcity of lymphoreticular tissue in these areas (15) . Therefore, the present case was noteworthy to be reported in view of the extranodal marginal zone MALT lymphoma that occurred in the conjunctivae in the post-transplant setting.
The major etiology of PTLD is the detrimental effect of immunosuppressive agents on the immune control of EBV and 60%∼80% of PLTD was associated with the virus (16, 17) . However, the pathogenesis of it is still unclear and very complex due to the interplay of many different factors, especially in EBV non-associated lymphoma (18) . The patient of this case had a past infection of EBV, but there was no evidence of viral reactivation or invasion to the tissue. Therefore, the authors concluded that the present case was EBV non-associated lymphoma. In cases of EBV-related PTLD, the reduction of immunosuppression has been a mainstay of PTLD treatment (19) . Rituximab, which is an anti-CD20 monoclonal antibody, is strongly suggested in a systemic disease (20) . This case was an EBV-negative lymphoma and the disease extent was limited to the eye; therefore, we decided that a local radiotherapy would be the treatment modality because radiotherapy is one of the competent options among the treatment modalities for orbital MALT lymphoma (21) (22) (23) (24) (25) . Recent studies reported that a radiotherapy dose range of 25∼35 Gy achieved ex-cellent survival rates for stage IEA orbital MALT lymphoma (26) . In addition, we changed tacrolimus to sirolimus for its anti-proliferative effect. Sirolimus is a macrolide antibiotic with immunosuppressive properties, and it was shown in vitro to suppress the growth of a number of lines of B-cell lymphomas (27) . The mechanism of the anti-proliferative effect of sirolimus is that the inhibition of interleukin-10 secretion induces apoptosis of the tumor cells.
Furthermore, the use of sirolimus instead of tacrolimus is safer than the reduction of immunosuppression in view of allograft rejection. Several cases reported a complete remission with good allograft function via sirolimus conversion without any chemotherapy (28, 29) . The patient of this case has maintained her allograft function without any sign of rejection during the treatment. PTLDs with EBV negativity have been known to have a poor prognosis with late onset (30) . However, orbital MALT lymphomas have a good prognosis in comparison with other ocular adnexal lymphomas despite EBV negativity (31) .
The patient achieved a complete remission after radiotherapy by careful clinical judgment. No additional radiologic studies were performed other than CT simulation for involved field radiation therapy. According to previous reports, follow-up CT or PET is not routinely performed in lymphoma to evaluate response (32) .
In conclusion, this report presents a case of conjunctival MALT lymphoma that produces visual discomfort in KT recipients. The patient received a lymphoma treatment with the conversion of the tacrolimus to sirolimus and a local radiotherapy without major complications or disease progression.
We suggest that the lymphoma should be suspected as a possible cause of visual disturbance in KT recipients when other common etiologies are ruled out.
